A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma

A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma

Vemurafenib, a selective inhibitor of oncogenic BRAF kinase carrying the V600 mutation, is approved for treatment of advanced BRAF mutation–positive melanoma. This study characterized mass balance, metabolism, rates/routes of elimination, and disposition of 14C-labeled vemurafenib in patients with m...

Full description

Bibliographic Details
Main Authors: Goldinger, Simone M, Rinderknecht, Jeannine, Dummer, Reinhard, Kuhn, Felix Pierre, Yang, Kuo-Hsiung, Lee, Lucy, Ayala, Ruben C, Racha, Jagdish, Geng, Wanping, Moore, David, Liu, Mei, Joe, Andrew K, Bazan, Selby Patricia Gil, Grippo, Joseph F
Format: Online
Language:English
Published: BlackWell Publishing Ltd 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324687/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324687/

Similar Items